Efficient therapeutic options in MDS are few: erythropoietin and hypomethylating agents (Azacitidine and Decitabine), immunomodulating agents (Lenalidomide) and recently, luspatercept (a TGFb-pathway activin receptor trap) [93]. This evidence concerns the gene TGFB1 and myelodysplastic syndrome.